Komipharm International Co. Ltd. has filed an emergency clinical trial plan with South Korea’s Ministry of Food and Drug Safety for its investigative drug Panaphix (PAX-1), to treat patients with novel coronavirus-related pneumonia.
The study, if approved, would be the first in the country for COVID-19, the respiratory disease caused by the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?